Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept
- Development stage
- Unknown
- Lead developer
- Medizinische Universität Graz Open Science
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
This entry represents a cohort of biological disease-modifying antirheumatic drugs (bDMARDs) evaluated in a clinical study by the Medical University of Graz. The study, "Ultrasound for bDMARD Withdrawal in RA" (NCT02064400), investigated whether musculoskeletal ultrasound could predict disease flares in rheumatoid arthritis patients who achieved clinical remission and subsequently discontinued their bDMARD therapy. The specific agents included in this cohort are the tumor necrosis factor (TNF) inhibitors etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab; the interleukin-6 (IL-6) receptor antagonist tocilizumab (spelled tozilizumab in the input); and the T-cell costimulation blocker abatacept. These drugs represent various mechanisms of action targeting the inflammatory cascade in autoimmune diseases and are typically used in combination with synthetic DMARDs like methotrexate.
- Brand names
- CimziaActemra
- Other names
- bDMARDsbiological DMARDs
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept.